Sanofi Sells Rilutek to Covis Pharma Sarl

April 4, 2013

Today, Covis Pharma Sarl, a Switzerland-based specialty pharmaceutical company, announced its agreement with sanofi-aventis U.S. LLC to acquire rights to Rilutek® (riluzole), which as you know is the only drug approved by the U.S. Food and Drug Administration (FDA) to treat ALS. Other compounds were also included in this aggregate sale. This international company has a U.S. affiliate, Covis Pharmaceuticals, in Cary, North Carolina.

More information on the sale of Rilutek can be found here.

Powered by Blackbaud
nonprofit software